WINTON GROUP Ltd Raises Stake in BioCryst Pharmaceuticals, Inc. $BCRX

WINTON GROUP Ltd boosted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 380.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 255,600 shares of the biotechnology company’s stock after purchasing an additional 202,384 shares during the quarter. WINTON GROUP Ltd owned approximately 0.10% of BioCryst Pharmaceuticals worth $2,556,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of BCRX. Royal Bank of Canada lifted its stake in BioCryst Pharmaceuticals by 2.4% in the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after purchasing an additional 1,458 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of BioCryst Pharmaceuticals by 6.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company’s stock worth $1,019,000 after purchasing an additional 8,517 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of BioCryst Pharmaceuticals by 49.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock worth $14,490,000 after purchasing an additional 640,704 shares during the period. Caxton Associates LLP purchased a new stake in shares of BioCryst Pharmaceuticals in the first quarter worth $314,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in BioCryst Pharmaceuticals by 11.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company’s stock valued at $3,363,000 after buying an additional 47,355 shares during the period. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Trading Down 2.1%

Shares of NASDAQ:BCRX opened at $8.12 on Friday. The stock has a market capitalization of $2.07 billion, a P/E ratio of -5.41 and a beta of 0.57. The stock’s 50-day moving average price is $9.65 and its 200-day moving average price is $9.23. BioCryst Pharmaceuticals, Inc. has a 12-month low of $6.00 and a 12-month high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The company had revenue of $218.25 million during the quarter, compared to analysts’ expectations of $183.28 million. During the same period in the prior year, the business posted $0.15 EPS. BioCryst Pharmaceuticals’s quarterly revenue was up 33.6% compared to the same quarter last year. As a group, research analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on BCRX. Weiss Ratings reiterated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Thursday, August 27th. HC Wainwright restated a “buy” rating and set a $32.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, June 30th. Cantor Fitzgerald lifted their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Tuesday, June 30th. Wedbush reduced their price objective on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $16.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday. Seven investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $20.40.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.